FluoretiQ Ltd
FluoretiQ (FQ) was founded in 2017 to solve the £1.1 Bn problem of using empirical antibiotic treatments as an alternative for accurate diagnostic information. We develop diagnostics that are fast accurate and can be used at the point-of-care ensuring the first prescription, is the right prescription.
We are building a family of diagnostic tools to dramatically improve the speed and quality of information available to every veterinarian and clinician.
NANOPLEX®– is an advanced latex agglutination test that rapidly identifies and quantifies bacteria within 15 minutes. NANOPLEX is our proprietary technology platform behind the first product to market: VERI-5 VET.
SCFI™– our second technology platform is a phenotypic, real-time and growth-free antibiotic susceptibility test that determines the most effective antibiotic within 30 minutes.
Meet the Team
Bio
Bill is a serial entrepreneur and exited founder. He holds an MSc in medical microbiology and has spent more than 30 years as a senior executive in the human healthcare sector, running commercial operations in the pharmaceutical, medical devices, and in-vitro diagnostics industries. He also brings a wealth of international experience from his time with Unipath (now Fisher Scientific), bioMerieux, and Bracco.
Bio
Neciah leads our company’s vision to safeguard antibiotic use with rapid bacterial diagnostics. Since co-founding the company in 2017, he has attracted grant and investment funding opportunities and forged long-term strategic partnerships to ensure patients receive the most effective antibiotic first time; Saving Time, Saving Money and most importantly Saving Lives.
Meet Josephine!
Josephine is a founder and co-inventor of FluoretiQ’s NANOPLEX™ technology, responsible for early development of concept to our prototype systems. She now leads our multi-disciplinary R&D team to translate our expertise into a fast and accurate diagnostic platform
Bio
Ben is the appointed representative of Deepbridge NED Limited and Head of Life Sciences at Deepbridge Capital. Prior to this role, Ben had been the managing director of Touchpoint Service and commercial director of Telmenow the healthcare equipment focussed e-commerce platform. Ben has also been chief commercial officer at Now Healthcare Group, a leading telemedicine provider with its Dr Now app.
Bio
Ben works closely with StartUp and ScaleUp businesses from across the South West, looking to grow their businesses. He is also an active Angel Investor and Funding and Support lead for South-West tech-cluster group, Tech South West.
Bio
Vicki started her career within the Tech industry in 2002, where she focused on managing SME financial affairs.
She is a Certified Accountant (ACCA) and stays involved with ACCA as the Chair for the Bristol Regional Panel and is a member of the Global Tech Forum.
Also, a Qualified Coach, NLP Practitioner, Accredited in DISC Personality Profiling and trained in Motivational Maps, Vicki brings those skills & experiences together to be a future focused strategic advisor to local businesses supporting in a Financial Director capacity.
Bio
Mr Kasra Saeb Parsy is a Consultant Urologist at Cambridge University Hospitals and Emergency Urology lead as well as National Urology Advisor for Nuffield Health. Kasra brings over 21 years of clinical experience to lead all clinical development, regulatory and medical affairs strategies for the Company. His goal is to bring a rapid and accurate point-of-care test to promote evidence based prescription and improve antibiotic stewardship within the NHS.
Bio
Sali Morris holds a PhD in Microbiology from University of Bath with over 4 years of experience in microbiology and molecular biology. Sali has experience developing rapid pathogen detection technologies having previously been part of a team developing a blood-culture independent, high throughput test for bloodstream infections.
Bio
Chrisann holds a BSc in Biomedical Sciences from University of West of England (UWE) and provides essential support for experimentation and successful lab operations.
Bio
Anna-Lisa works as advisor, NED, Chair, bringing her productive network, deep strategy and leadership skill and experience scaling DeepTech startups to an active portfolio of science-led technology startups and scaleups. Anna-Lisa is Entrepreneur in Residence at SETsquared Bristol, Training and Coaching Lead at the Royal Academy of Engineering’s Shott scale-up programme and was Non-Executive Chair of biomedical device startup Emm Tech from 2021 to 2023.
Bio
Martin is a Professor of Applied Electromagnetics at University of Bristol with 30 years experience in electronic and photonic device research and development
Bio
Carmen is a Professor of Organic and Biological Chemistry at University of Bristol and currently Principal investigator on 2 collaborative projects with FluoretiQ. Her expertise in synthetic glycan chemistry has help shaped the backbone of our NANOPLEX probe chemistry.
James Spencer
Scientific Advisor
Bio
Jim is a Reader in Microbiology at University of Bristol and a co-investigator on 2 collaborative projects with FluoretiQ. His work in microbiology and AMR drives continuous improvement of the NANOPLEX technology.
Bio
Chris has over 30 years of experience in the veterinary profession and pharmaceutical sales, including roles as Sales Director and at a startup pharmaceutical company. Over the last 8 years, Chris held the position of Commercial Manager in the UK and Ireland at IVC Evidensia, Europe’s largest Veterinary Group.
Bio
Pete Corish has 20 years of experience in core clinical laboratory, Point-of-Care immunoassay, and molecular diagnostics markets, with a focus on commercialising R&D and sourcing third-party innovative technologies in a number of Life Science and IVD businesses in the UK and US. As the former Chief Technology Officer of BBI Solutions, a leading independent provider of diagnostic reagents and services, Pete was responsible for M&A, Commercial Strategic Partnerships and technology licensing/R&D, building out their product and innovative technology portfolios.
Bio
Director of PH Clinical Ltd supplying consultancy and advisory support to UK Healthcare Companies and with Sales, Marketing and Clinical Research Expertise to SMEs through Deepbridge Capital NED Team. Has over 35 years experience in The Pharmaceutical Industry and with NIHR Business Development Team creating over 30 key partnerships for Greater Manchester Clinical Research Network.
Bio
Tom is a Healthcare strategist with 2 decades of clinical experience as a GP and Pharmacist. He has expertise in Antimicrobial Resistance (AMR); its science, economics and policy reform. He guided the successful application of a novel antimicrobial drug, active against severe drug resistant infections, within the world’s first volume de-linked economic model. He is also the co-founder of the Infection Management Coalition which maps a future ecosystem for severe infections, sepsis and pandemic preparedness.
Bio
Matthew is a seasoned entrepreneurial Life Science business professional with operational, sales and commercialisation and board experience across Pharma-Biotech R&D & Clinical Development, CROs, Strategic Consultancy, Business Intelligence, Licensing and Digital Health. Matthew’s focus is on market entry strategies, commercialisation and partnership building.